News that U.K.-based GlaxoSmithKline (GSK) filed a WARN letter with the state of Pennsylvania indicating another 150 people would be laid off in its commercial and research and development group near Philadelphia, and that it would simultaneously relocate another R&D unit to Maryland, has the community buzzing. In our most recent poll, BioSpace (DHX) wanted to know if you think Pharm Country will do what it takes to keep biotech jobs in the area? The answer was a resounding yes, with 69 percent of the 307 respondents saying they believe that Pennsylvania officials will continue to offer tax breaks and other labor benefits to keep biotech booming in the region. Click here to read more.
04/06/15 | In the News
